Emtricitabin, Tenofovir-alafenamid a Rilpivirin
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1382/2022-SML | 19. 08. 2022 | Gilead Sciences s.r.o. | 19 946 649,00 | 18 133 318,00 | 19 946 649,00 | 18 133 318,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Emtricitabin, Tenofovir-alafenamid a Rilpivirin_EP.pdf | Písemná zpráva zadavatele | 29. 08. 2022 10:14 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 19 946 649,00 | 18 133 318,00 | CZK |
Price Actually Paid in Each Year of Performance
| 1382/2022-SML | 2023 | 5 177 644,73 | 4 706 949,75 |